Head to head

CJC-1295 with DAC vs Sermorelin

GH secretagogue

A comparison decided mostly by evidence: Sermorelin has been studied in people to a degree the other has not.

Verdict

Sermorelin rests on firmer evidence

If your priority is the compound with the strongest published support, that is Sermorelin. CJC-1295 with DAC is not therefore worse — it is less examined, which is a different thing — but the gap is the single most defensible difference on this page, and it is the one most comparisons quietly skip.

What you are actually choosing between

Both are classed here as growth hormone secretagogues, so this is a within-class choice: the mechanism is broadly shared and what separates them is kinetics, route, and how much has actually been tested.

The overlap is muscle growth and recovery and sleep. On this site's goal weighting — an editorial priority score, not a measure of effect size — CJC-1295 with DAC rates 4/5 for muscle growth and Sermorelin rates 3/5.

The evidence

This is the part that decides most of it. Sermorelin has approval from a regulator somewhere, though not a current FDA or EMA label — it was FDA approved as Geref, then withdrawn for commercial reasons. CJC-1295 with DAC has some human data, but it is small, old, or uncontrolled — phase 1 single-dose studies only; development was discontinued. That gap is the headline, and it is a statement about the literature rather than a promise about you: a compound with trial data can still do nothing for your case, and one without it is unproven rather than disproven.

How they differ in practice

Kinetics are not close. CJC-1295 with DAC has a half-life of 7 days against Sermorelin's 12 min — more than two orders of magnitude — which is why one is dosed once a week and the other once daily. A long half-life means a steadier level and a mistake you cannot take back for days; a short one means timing matters and a bad day washes out fast.

Risk and difficulty

Sermorelin is rated beginner here and CJC-1295 with DAC intermediate. That rating is about how much can go wrong in handling, dosing and monitoring, not about how well either works.

Source notes

What the evidence actually says

Verbatim, so you can check the verdict above against what it was built from.

CJC-1295 with DAC

Dosed once weekly at 1 to 2 mg, which is how it is overwhelmingly run in practice: the albumin binding makes the weekly total the meaningful quantity, and splitting it across the week buys nothing. A GHRH (1-29) analogue carrying a Drug Affinity Complex maleimide that binds serum albumin, which is the ONLY reason it differs from the no-DAC version: the terminal half-life runs roughly 6 to 8 days instead of minutes, so a single dose produces a sustained rise in GH and IGF-1 rather than a discrete pulse. Phase 1 human dosing studies used single subcutaneous doses of about 30 to 250 mcg/kg. Development was discontinued and it is NOT approved by any regulator; consumer supply is research-chemical grade. Because exposure is continuous rather than pulsatile, it is the less physiologic of the two CJC-1295 forms and carries more of the water-retention and glucose signal.

Sermorelin

Synthetic analogue of the first 29 amino acids of GHRH. Previously approved in the US as Geref for paediatric GH deficiency and used as a diagnostic agent, then withdrawn from the market for commercial reasons. Because it works through the pituitary it preserves pulsatile GH release, but modern adult data is thin and most anti-ageing dosing is extrapolated from that older clinical use.

Side by side

The numbers

CJC-1295 with DAC compared with Sermorelin
Attribute	CJC-1295 with DAC	Sermorelin
Class	GH secretagogue	GH secretagogue
Routes	Subcutaneous	Subcutaneous
Dose range	1 mg–2 mg (typical 1.5 mg)	100 mcg–1 mg (typical 300 mcg)
Frequency	Once a week	Once daily
Half-life	7 days	12 min
Cycle length	12 weeks	12 weeks
Experience	Intermediate	Beginner
Evidence	Limited human data	Approved elsewhere
Contraindications	Pregnant / nursing Active malignancy Under 18	Pregnant / nursing Active malignancy Under 18
Side effects	Water retention and puffiness, more pronounced than with short-acting GHRHs Injection site redness or swelling Head rush, flushing or transient dizziness Tingling or numbness in the hands, which can reflect carpal tunnel pressure Reduced insulin sensitivity and higher fasting glucose with sustained elevation Lethargy or headache, often reported in the first week	Injection site redness, swelling or itching Flushing shortly after dosing Headache or transient dizziness Water retention and tingling in the hands Vivid dreams or drowsiness when dosed pre-bed

Turn a typical dose into a mark on the syringe: CJC-1295 with DACSermorelin

Goals

Where they overlap, and where they do not

Goal	CJC-1295 with DAC	Sermorelin
muscle growth	CJC-1295 with DAC: 4/5	Sermorelin: 3/5
recovery and sleep	CJC-1295 with DAC: 3/5	Sermorelin: 4/5
injury repair	CJC-1295 with DAC: 3/5	Sermorelin: 2/5
longevity	CJC-1295 with DAC: 2/5	Sermorelin: 3/5
fat loss	CJC-1295 with DAC: 2/5	Sermorelin: 2/5

They overlap on 5 goals and diverge on 0. Weights are this site’s editorial priority score out of 5 — how central a goal is to why people use a compound. They are not effect sizes and two 5s do not mean two equal results.

Go deeper

MonographCJC-1295 with DACMechanism, protocol, storage, sources.MonographSermorelinMechanism, protocol, storage, sources.ToolReconstitution calculatorTurn either dose above into a mark on the syringe.

Other comparisons with these two

Educational information only, not medical advice. Talk to a licensed clinician before starting, changing, or stopping anything.